The novel, orally active, delta opioid RWJ-394674 is biotransformed to the potent mu opioid RWJ-413216

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 3, 2006, Pages 1273-1279

  Codd, E E ^a,b   Carson, J R ^a   Colburn, R W ^a   Dax, S L ^a   Desai Krieger, D ^a   Martinez, R P ^a   McKown, L A ^a   Neilson, L A ^a   Pitis, P M ^a   Stahle, P L ^a   Stone, D J ^a   Streeter, A J ^a   Wu, W N ^a   Zhang, S P ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Johnson and Johnson   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[N,N DIETHYL 4 [(8 PHENETHYL 8 AZABICYCLO [3.2.1]OCT 3 YLIDENE)PHENYLMETHYL]BENZAMIDE]; DELTA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR AGONIST; NALOXONE; NALTRINDOLE; RWJ 394674; RWJ 413216; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; IN VITRO STUDY; LIVER MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SEDATION;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; FEMALE; MALE; MICE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU;

EID: 33747611706     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.104208     Document Type: Article

References (25)

1. Bernard D, Coop A, and MacKerell AD Jr (2003) 2D conformationally sampled pharmacophore: a ligand-based pharmacophore to differentiate δ opioid agonists from antagonists. J Am Chem Soc 125:3101-3107.
2. Bilsky EJ, Calderon SN, Wang T, Bernstein RN, Davis P, Hruby VJ, McNutt RW, Rothman RB, Rice KC, and Porreca F (1995) SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J Pharmacol Exp Ther 273:359-366.
3. Carson JR, Coats SJ, Codd EE, Dax SL, Lee J, Martinez RP, McKown LA, Neilson LA, Pitis PM, Wu W-N, et al. (2004a) N-alkyl-4-[(8-azabicyclo[3.2.1]- oct-3-ylidene)phenylmethyl]benzamides, μ and δ opioid agonists: a μ address. Bioorg Med Chem Lett 14:2113-2116.
4. Carson JR, Coats SJ, Codd EE, Dax SL, Lee J, Martinez RP, Neilson LA, Pitis PM, and Zhang S-P (2004b) N,N-dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3- ylidene)phenylmethyl] benzamides, potent, selective δ opioid agonists. Bioorg Med Chem Lett 14:2109-2112.
5. Chang KJ, Rigdon GC, Howard JL, and McNutt RW (1993) A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. J Pharmacol Exp Ther 267:852-857.
6. Chaturvedi K, Jiang X, Christoffers KH, Chinen N, Bandari P, Raveglia LF, Ronzoni S, Dondio G, and Howells RD (2000) Pharmacological profiles of selective nonpeptidic delta opioid receptor ligands: brain research. Mol Brain Res 80:166-176.
7. Codd EE, Shank RP, Schupsky JJ, and Raffa RB (1995) Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 274:1263-1270.
8. Collier HO, Dinneen LC, Johnson CA, and Schneider C (1968) The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br J Pharmacol 32:295-310.
9. Comer SD, Hoenicke EM, Sable AI, McNutt RW, Chang KJ, De Costa BR, Mosberg HI, and Woods JH (1993) Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 267:888-895.
10. Dondio G, Ronzoni S, Eggleston DS, Artico M, Petrillo P, Petrone G, Visentin L, Farina C, Vecchietti V, and Clarke GD (1997) Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective δ opioid agonists, based on an extension of the message-address concept. J Med Chem 40: 3192-3198.
11. Dondio G, Ronzoni S, Farina C, Graziani D, Parini C, Petrillo P, and Giardina GA (2001) Selective delta opioid receptor agonists for inflammatory and neuropathic pain. Farmaco 56:117-119.
12. Eddy NB and Leimbach D (1953) Synthetic analgesics: II. Dithienylbutenylamines and dithienylbutylamines. J Pharmacol Exp Ther 107:385-393.
13. Hong EJ, Rice KC, Calderon S, Woods JH, and Traynor JR (1998) Convulsive behavior of nonpeptide δ-opioid ligands: comparison of SNC80 and BW373U86 in mice. Analgesia (Elmsford N Y) 3:269-276.
14. Jiang Q, Mosberg HI, and Porreca F (1990) Selective modulation of morphine antinociception, but not development of tolerance, by δ receptor agonists. Eur J Pharmacol 186:137-141.
15. Kamei J, Saitoh A, Ohsawa M, Suzuki T, Misawa M, Nagase H, and Kasuya Y (1995) Antinociceptive effects of the selective non-peptidic δ-opioid receptor agonist TAN-67 in diabetic mice. Eur J Pharmacol 276:131-135.
16. Litchfield JT Jr and Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113.
17. McNaughton N, Pritchard S, and Jarvie E (2003) Low efficacy of delta opioid receptor agonists including UK321,130 and ARM-390 imply neonatal DRG receptors are not homomeric (Abstract). Soc Neurosci Abstr 33:480.485.
18. Nagase H, Kawai K, Hayakawa J, Wakita H, Mizusuna A, Matsuura H, Tajima C, Takezawa Y, and Endoh T (1998) Rational drug design and synthesis of a highly selective nonpeptide delta-opioid agonist, (4aS*,12aR*)-4a-(3- hydroxyphenyl)-2-methyl- 1,2,3,4,4a,5,12,12a-octahydropyrido[3,4-b]acridine (TAN-67). Chem Pharm Bull 46:1695-1702.
19. Nitsche JF, Schuller AGP, King MA, Zengh M, Pasternak GW, and Pintar JE (2002) Genetic dissociation of opiate tolerance and physical dependence in δ-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 22:10906-10913.
20. O'Callaghan JP and Holtzman SG (1975) Quantification on the analgesic activity of narcotic antagonists by a modified hot-plate procedure. J Pharmacol Exp Ther 192:497-505.
21. Petrillo P, Angelici O, Bingham S, Ficalora G, Garnier M, Zaratin PF, Petrone G, Pozzi O, Sbacchi M, Stean TO, et al. (2003) Evidence for a selective role of the δ-opioid agonist [8R-(4bS*,8aa,8ab,12bb)]7,10-dimethyl- 1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9h)-4,8- methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses. J Pharmacol Exp Ther 307:1079-1089.
22. Schetz JA, Calderon SN, Bertha CM, Rice K, and Porreca F (1996) Rapid in vivo metabolism of a methylether derivative of (+/-)-BW373U86: the metabolic fate of [3H]SNC121 in rats. J Pharmacol Exp Ther 279:1069-1076.
23. Su Y-F, McNutt RW, and Chang K-J (1998) Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. J Pharmacol Exp Ther 287:815-823.
24. Vankova ME, Weinger MB, Chen D-Y, Bronson JB, Motis V, and Koob GF (1996) Role of central mu, delta-1, and kappa-1 opioid receptors in opioid-induced muscle rigidity in the rat. Anesthesiology 85:574-583.
25. Wild KD, McCormick J, Bilsky EJ, Vanderah T, McNutt RW, Chang KJ, and Porreca F (1993) Antinociceptive actions of BW373U86 in the mouse. J Pharmacol Exp Ther 267:858-865.